JP Morgan Chase
ACTU

JP Morgan Chase’s Actuate Therapeutics ACTU Stock Holding History

JP Morgan Chase’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.85K Buy
3,863
+68
+2% +$282 ﹤0.01% 6771
2025
Q4 		$23.2K Buy
3,795
+1,311
+53% +$9.01K ﹤0.01% 6467
2025
Q3 		$16.6K Sell
2,484
-296
-11% -$2.15K ﹤0.01% 6520
2025
Q2 		$17K Buy
+2,780
New +$24.3K ﹤0.01% 6210
2025
Q1 		– Sell
-3
Closed -$24 – 7817
2024
Q4 		$24 Buy
+3
New +$24 ﹤0.01% 7247

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's ACTU Position: Q1 2026 in Review

JP Morgan Chase increased its Actuate Therapeutics (ACTU) stake by 1.8% in Q1 2026, buying an estimated $282 and bringing the position to 3,863 shares worth $8.85K. The position accounts for ﹤0.01% of the portfolio, ranked #6771.

JP Morgan Chase first reported a position in ACTU in Q4 2024 and has held it in 5 quarters since. The position peaked at $23.2K in Q4 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • JP Morgan Chase held 3,863 shares of Actuate Therapeutics worth $8.85K as of Q1 2026.
  • JP Morgan Chase bought 68 Actuate Therapeutics shares in Q1 2026, an estimated $282.
  • Actuate Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6771 holding.
  • JP Morgan Chase first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • JP Morgan Chase's Actuate Therapeutics position peaked at $23.2K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.